Gut microbiota trigger influenced by tyrosine kinase inhibitors in mice

Gut microbial dysbiosis has been found in patients undergoing tyrosine kinase inhibitors treatment. To investigate whether the gut microbiota is altered by oral anlotinib administration, 16S rRNA sequencing was performed on intestinal contents from mice.

已有研究发现，接受酪氨酸激酶抑制剂（tyrosine kinase inhibitors）治疗的患者存在肠道微生物群失调。为探究口服安罗替尼给药是否会改变肠道微生物群，研究人员对小鼠的肠道内容物开展了16S核糖体RNA（16S rRNA）测序。